Cargando…
Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC
For antibody-drug conjugates (ADCs) that carry a cytotoxic drug, doses that can be administered in preclinical studies are typically limited by tolerability, leading to a narrow dose range that can be tested. For molecules with non-linear pharmacokinetics (PK), this limited dose range may be insuffi...
Autores principales: | Figueroa, Isabel, Leipold, Doug, Leong, Steve, Zheng, Bing, Triguero-Carrasco, Montserrat, Fourie-O'Donohue, Aimee, Kozak, Katherine R., Xu, Keyang, Schutten, Melissa, Wang, Hong, Polson, Andrew G., Kamath, Amrita V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150628/ https://www.ncbi.nlm.nih.gov/pubmed/29757698 http://dx.doi.org/10.1080/19420862.2018.1465160 |
Ejemplares similares
-
Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
por: Leipold, Douglas D., et al.
Publicado: (2018) -
ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023) -
Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)
por: Mahmood, Iftekhar
Publicado: (2021) -
Site-Specific Antibody Conjugation for ADC and Beyond
por: Zhou, Qun
Publicado: (2017) -
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
por: Nguyen, Toan D., et al.
Publicado: (2023)